1. Home
  2. APGE vs HSAI Comparison

APGE vs HSAI Comparison

Compare APGE & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APGE
  • HSAI
  • Stock Information
  • Founded
  • APGE 2022
  • HSAI 2014
  • Country
  • APGE United States
  • HSAI China
  • Employees
  • APGE N/A
  • HSAI N/A
  • Industry
  • APGE Biotechnology: Biological Products (No Diagnostic Substances)
  • HSAI
  • Sector
  • APGE Health Care
  • HSAI
  • Exchange
  • APGE Nasdaq
  • HSAI Nasdaq
  • Market Cap
  • APGE 2.1B
  • HSAI 1.8B
  • IPO Year
  • APGE 2023
  • HSAI 2023
  • Fundamental
  • Price
  • APGE $37.29
  • HSAI $16.36
  • Analyst Decision
  • APGE Strong Buy
  • HSAI
  • Analyst Count
  • APGE 4
  • HSAI 0
  • Target Price
  • APGE $91.33
  • HSAI N/A
  • AVG Volume (30 Days)
  • APGE 545.3K
  • HSAI 6.1M
  • Earning Date
  • APGE 05-20-2025
  • HSAI 05-26-2025
  • Dividend Yield
  • APGE N/A
  • HSAI N/A
  • EPS Growth
  • APGE N/A
  • HSAI N/A
  • EPS
  • APGE N/A
  • HSAI N/A
  • Revenue
  • APGE N/A
  • HSAI $284,577,139.00
  • Revenue This Year
  • APGE N/A
  • HSAI $68.50
  • Revenue Next Year
  • APGE $743.14
  • HSAI $35.77
  • P/E Ratio
  • APGE N/A
  • HSAI N/A
  • Revenue Growth
  • APGE N/A
  • HSAI 10.66
  • 52 Week Low
  • APGE $26.20
  • HSAI $3.52
  • 52 Week High
  • APGE $63.50
  • HSAI $24.18
  • Technical
  • Relative Strength Index (RSI)
  • APGE 52.37
  • HSAI 51.78
  • Support Level
  • APGE $34.38
  • HSAI $17.18
  • Resistance Level
  • APGE $41.05
  • HSAI $19.40
  • Average True Range (ATR)
  • APGE 2.23
  • HSAI 1.42
  • MACD
  • APGE 0.10
  • HSAI 0.21
  • Stochastic Oscillator
  • APGE 51.48
  • HSAI 58.64

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. The Group organized its operations into two segments: the LiDAR segment and the gas detection segment, out of which LiDAR segments derives maximum revenue. Geographically, the company operates into North America, Mainland China, Europe and Other regions.

Share on Social Networks: